Kallikreins are being investigated as potential serum markers for adenocarcinomas such as prostate (KLK2), breast (KLK10, 12, 13) and ovary (KLK6, 8, 10, 11) (Diamandis and Yousef, 2002) (Figure 2C). This evidence concerns the gene KLK4 and adenocarcinoma.